“… 59 , 60 Nowadays, the highlights of clinical practice and research for anti-VEGF therapy are beyond the efficacy, and safety but the selection of the optimal treatment and the balance for health economics between the risks and benefits, for example, the prefer for ranibizumab or bevacizumab in neovascular AMD, 43 and the choices between aflibercept monotherapy or bevacizumab first in DME. 61 Third, with the high and increasing incidence, and the heavy disease burden of DED, MGD, and myopia, 27 , 62 , 63 , 64 , 65 , 66 especially the rapidly increasing of DED, MGD, and myopia related to more reliance on electronic screens and DED or MGD related to more reliance on the mask during the COVID-19 pandemic, 67 , 68 , 69 , 70 , 71 and with the novel therapies for myopia, DED, and MGD such as orthokeratology, atropine and botanical formula, 29 , 72 the requirement for high-quality evidence of interventions for DED, MGD and myopia has increased rapidly in recent years, which could explain in part the recent and future hotspots of DED, MGD and myopia in the field of worldwide ophthalmologic RCTs. Taken together, over the past two decades, anti-VEGF therapy for retinopathy such as AMD and DME, DED, the use of new ophthalmologic diagnostic tools, and myopic were the hottest research highlights.…”